HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Lai-Ming Ching Selected Research

vadimezan

3/2014Efficacy against subcutaneous or intracranial murine GL261 gliomas in relation to the concentration of the vascular-disrupting agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), in the brain and plasma.
11/2011Activation of mitogen-activated protein kinases by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) plays an important role in macrophage stimulation.
9/2010Labeling of oxidizable proteins with a photoactivatable analog of the antitumor agent DMXAA: evidence for redox signaling in its mode of action.
4/2010Activation of the nucleotide oligomerization domain signaling pathway by the non-bacterially derived xanthone drug 5'6-dimethylxanthenone-4-acetic acid (Vadimezan).
8/2009Neutrophil influx and chemokine production during the early phases of the antitumor response to the vascular disrupting agent DMXAA (ASA404).
6/2009Enhancement of the action of the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA; ASA404) by non-steroidal anti-inflammatory drugs.
3/2008IFN-beta-dependent inhibition of tumor growth by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
3/2008Consequences of increased vascular permeability induced by treatment of mice with 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and thalidomide.
7/2007The vascular disrupting agent, DMXAA, directly activates dendritic cells through a MyD88-independent mechanism and generates antitumor cytotoxic T lymphocytes.
4/2007Antitumour action of 5,6-dimethylxanthenone-4-acetic acid in rats bearing chemically induced primary mammary tumours.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Lai-Ming Ching Research Topics

Disease

28Neoplasms (Cancer)
01/2021 - 01/2002
10Necrosis
03/2014 - 03/2004
4Multiple Myeloma
09/2004 - 05/2003
2Glioma (Gliomas)
11/2018 - 03/2014
2Ovarian Neoplasms (Ovarian Cancer)
01/2018 - 08/2010
2Hypoxia (Hypoxemia)
04/2014 - 08/2006
2Mesothelioma
04/2010 - 12/2005
2Adenocarcinoma
06/2009 - 08/2005
2Lung Neoplasms (Lung Cancer)
03/2008 - 12/2005
1Breast Neoplasms (Breast Cancer)
09/2020
1Carcinoma (Carcinomatosis)
09/2020
1Circulating Neoplastic Cells
09/2020
1Cataract (Cataracts)
09/2015
1Wounds and Injuries (Trauma)
04/2014
1Chronic Disease (Chronic Diseases)
04/2014
1Glioblastoma (Glioblastoma Multiforme)
03/2014
1Pre-Eclampsia (Preeclampsia)
05/2010
1Vascular System Injuries
06/2009
1Adenocarcinoma of Lung
03/2008
1Thymoma (Thymic Carcinoma)
07/2007
1Inflammation (Inflammations)
08/2006
1Lymphoma (Lymphomas)
01/2005

Drug/Important Bio-Agent (IBA)

21vadimezanIBA
03/2014 - 01/2002
8CytokinesIBA
11/2011 - 01/2002
5Thalidomide (Thalomid)FDA Link
09/2004 - 09/2002
4Tryptophan (L-Tryptophan)FDA Link
01/2021 - 03/2013
4NF-kappa B (NF-kB)IBA
04/2010 - 01/2002
4Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
08/2007 - 08/2005
3Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)IBA
01/2021 - 03/2013
3EnzymesIBA
01/2021 - 03/2013
3Pharmaceutical PreparationsIBA
08/2006 - 01/2002
2AntigensIBA
09/2020 - 07/2007
2AcidsIBA
03/2014 - 08/2005
2ChemokinesIBA
11/2011 - 08/2009
2Proteins (Proteins, Gene)FDA Link
08/2010 - 04/2010
1Tryptophan Oxygenase (Tryptophan 2,3 Dioxygenase)IBA
01/2021
1MicroRNAs (MicroRNA)IBA
09/2020
1Cell-Free Nucleic AcidsIBA
09/2020
1Biomarkers (Surrogate Marker)IBA
09/2020
1Volatile Organic CompoundsIBA
09/2020
1DNA (Deoxyribonucleic Acid)IBA
09/2020
1Nucleic AcidsIBA
09/2020
1Estrogens (Estrogen)FDA Link
01/2018
1CalreticulinIBA
01/2018
1Hormones (Hormone)IBA
01/2018
1KynurenineIBA
09/2015
1ConnexinsIBA
04/2014
1Angiogenesis InhibitorsIBA
04/2014
1Bevacizumab (Avastin)FDA Link
03/2014
1LuciferasesIBA
03/2014
1UbiquitinIBA
08/2010
1Proteasome Endopeptidase Complex (Proteasome)IBA
08/2010
1A-factor (Streptomyces)IBA
05/2010
1NLR ProteinsIBA
04/2010
1Phosphotransferases (Kinase)IBA
04/2010
1Chemokine CXCL10IBA
04/2010
1Messenger RNA (mRNA)IBA
04/2010
1Small Interfering RNA (siRNA)IBA
04/2010
1Biological ProductsIBA
04/2010
1LigandsIBA
04/2010
1xanthoneIBA
04/2010
1rofecoxib (Vioxx)FDA Link
06/2009
1Ibuprofen (Motrin)FDA LinkGeneric
06/2009
1Celecoxib (Celebrex)FDA Link
06/2009
1ProstaglandinsIBA
06/2009
1Diclofenac (SR 38)FDA LinkGeneric
06/2009
1Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA
06/2009
1SalicylatesIBA
06/2009
1OvalbuminIBA
07/2007
1combretastatinIBA
07/2007
1Acetic Acid (Vinegar)FDA LinkGeneric
01/2007
1PerforinIBA
12/2005
1Evans Blue (Blue, Evans)FDA Link
08/2005
1Serotonin (5 Hydroxytryptamine)IBA
08/2005
1Type I Tumor Necrosis Factor ReceptorsIBA
08/2005
1AlbuminsIBA
08/2005
1bisbenzimide ethoxide trihydrochloride (Hoechst 33342)IBA
08/2005
1Cyclophosphamide (Cytoxan)FDA LinkGeneric
05/2004
1Interferon-gamma (Interferon, gamma)IBA
03/2004
1Therapeutic UsesIBA
05/2003
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
05/2003
1SiliconIBA
01/2002

Therapy/Procedure

3Therapeutics
04/2014 - 05/2003
3Drug Therapy (Chemotherapy)
03/2008 - 09/2002
1Radiotherapy
04/2014
1Immunotherapy
08/2006
1Aftercare (After-Treatment)
01/2003